Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Pfizer Inc.
< Previous
1
2
3
4
5
6
7
8
9
Next >
Pfizer Oncology Hosts Innovation Day, Highlighting Fully Integrated Organization, Robust Portfolio, and Strategic Priorities to Drive Long-Term Sustainable Growth
February 29, 2024
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Announces Positive Top-Line Data for Full Season Two Efficacy of ABRYSVO® for RSV in Older Adults
February 29, 2024
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
February 26, 2024
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
European Commission Approves Pfizer’s VELSIPITY® for Patients with Moderately to Severely Active Ulcerative Colitis
February 19, 2024
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Invites Public to Register for Webcast of Pfizer Oncology Innovation Day
February 15, 2024
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Breaking Barriers in Cancer Care: The American Cancer Society and Pfizer Announce a $15 Million, Three-Year Initiative to Bridge the Gap in Cancer Care Disparities
February 05, 2024
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Reports Full-Year 2023 Results and Reaffirms Full-Year 2024 Financial Guidance
January 30, 2024
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
European Medicines Agency Validates Type II Variation Application for PADCEV® (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
January 26, 2024
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Recommends Shareholders Reject the Below-Market Mini-Tender Offer by TRC Capital Investment Corporation
January 10, 2024
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
TIVDAK® Supplemental Biologics License Application Accepted for Priority Review by FDA for Patients with Recurrent or Metastatic Cervical Cancer
January 09, 2024
From
Pfizer Inc.
Via
Business Wire
Tickers
GMAB
PFE
European Commission Approves Pfizer’s TALZENNA® in Combination with XTANDI® for Adult Patients with Metastatic Castration-Resistant Prostate Cancer
January 08, 2024
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
January 02, 2024
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Invites Public to View and Listen to Webcast of January 30 Conference Call with Analysts
December 19, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer
December 15, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Declares First-Quarter 2024 Dividend
December 14, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Completes Acquisition of Seagen
December 14, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Provides Full-Year 2024 Guidance
December 13, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Receives All Required Regulatory Approvals to Complete the Acquisition of Seagen
December 12, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
FDA and EMA Accept Marstacimab Regulatory Submissions for the Treatment of Hemophilia A and B
December 11, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Marstacimab Phase 3 Data Presented at ASH 2023 Demonstrate Significant Bleed Reduction in Hemophilia A and B
December 09, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
European Commission Approves Pfizer’s ELREXFIO® for Relapsed and Refractory Multiple Myeloma
December 08, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Announces Topline Phase 2b Results of Oral GLP-1R Agonist, Danuglipron, in Adults with Obesity
December 01, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
November 21, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Highlights Scientific Advances from Growing Hematology Portfolio at American Society of Hematology Annual Meeting
November 02, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
November 02, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Reports Third-Quarter 2023 Results
October 31, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19
October 26, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
BNTX
PFE
FDA Approves PENBRAYA™, the First and Only Vaccine for the Prevention of the Five Most Common Serogroups Causing Meningococcal Disease in Adolescents
October 20, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Amends U.S. Government Paxlovid Supply Agreement and Updates Full-Year 2023 Guidance
October 13, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
U.S. FDA Approves Pfizer’s VELSIPITY™ for Adults with Moderately to Severely Active Ulcerative Colitis (UC)
October 13, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.